Article
Efficacy of Tenapanor in Managing Hyperphosphatemia and Constipation in Hemodialysis Patients: A Randomized Controlled Trial
2025-02-03
Abstract excerpt
<h4>Introduction</h4> Tenapanor is a minimally absorbed, small-molecule inhibitor of sodium/hydrogen exchanger 3 and thus suppresses sodium absorption in the gastrointestinal tract. It is approved by the FDA for the treatment of hyperphosphatemia in dialysis patients. This randomized controlled trial evaluated its efficacy in the treatment of hyperphosphatemia and constipation in hemodialysis patients. <h4>Methods...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 2968de63-b983-5c47-9ba6-b9605620e8f7
- DOI
- 10.1101/2025.02.02.25321552
